Komori
Stella Pharma (4888) · InitiativeFirst stated

Drug Supply for a Study of FBPA-PET-Positive Refractory Malignant Tumors at Shonan Kamakura General Hospital

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Supply of investigational drugs for FBPA-PET research to Shonan Kamakura General HospitalA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「In February 2026, we also entered into an agreement to supply the drug product to be used in a study conducted with Shonan Kamakura General Hospital, Tokushukai Medical Corporation, examining the efficacy and safety of BNCT in patients with FBPA-PET-positive refractory malignant tumors.」

    In February 2026, an agreement was entered into to supply drugs to Shonan Kamakura General Hospital for a study targeting patients with FBPA-PET-positive refractory malignant tumors.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Stella Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Drug Supply for a Study of FBPA-PET-Positive Refractory Malignant Tumors at Shonan Kamakura General Hospital | STELLA PHARMA CORPORATION (4888) | Komori